GlassScriptPhysician profile
Aijaz Khan
NPI 1912984063
$6,319.18
in general payments reported to CMS, 2019-2025
39 companies · $694 in 2025
The $694 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $901 · 2021: $1,212 · 2022: $1,051 · 2023: $726 · 2024: $693 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,113.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $712.76 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $569.84 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $434.57 | 2020-2024 | Farxiga, Lokelma |
| Allergan, INC. | $414.11 | 2019-2020 | |
| Amarin Pharma, INC. | $400.67 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.58 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $322.48 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $311.73 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $309.50 | 2019-2023 | Invega Trinza, Invega Sustenna, Xarelto |
| Acadia Pharmaceuticals INC | $307.10 | 2020-2023 | Nuplazid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $257.67 | 2022-2025 | Caplyta |
| Amgen INC. | $232.02 | 2020-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $185.43 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Steris Corporation | $141.55 | 2024 | |
| Redhill Biopharma INC. | $128.44 | 2020-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aijaz Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.